|
Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology - Pretax loss widens to £7.7 million for 2022 from £6.3 million in 2021. Administrative expenses increase to £7.4 million from £6.0 million a year earlier. Research & development expenditure amounts to £4.9 million, up from £3.7 million in 2021. Looking ahead, Destiny Pharma says it will focus on completing the manufacturing scale-up to deliver clinical trial material for the NTCD-M3 clinical programme being run by our partner Sebela. Chief Executive Officer Neil Clark says: ‘Destiny Pharma has made good progress in 2022 and in the first quarter of 2023.’ Current stock price: 30.10 pence, down 1.3% on Thursday afternoon in London 12-month change: down 39% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
